Moderna Inc. (MRNA)
Moderna Beats on Q1 Earnings, Lags on Revenues, Focuses on Cost Cuts
MRNA reports mixed Q1 results. The company reiterates 2025 sales guidance but announces a cost-cutting initiative to reduce expenses significantly by 2027.
Moderna, Inc. (MRNA) Q1 2025 Earnings Call Transcript
Moderna, Inc. (NASDAQ:MRNA ) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Lavina Talukdar - Senior Vice President, Investor Relations Stephane Bancel - Chief Executive Officer Jamey Mock - Chief Financial Officer Stephen Hoge - President Conference Call Participants Salveen Richter - Goldman Sachs Tyler Van Buren - TD Cowen Cory Kasimov - Evercore ISI Courtney Breen - Bernstein Dick Gottfred - William Blair Gena Wang - Barclays Operator Good day, and thank you for standing by. Welcome to the Moderna First Quarter 2025 Conference Call.
Moderna (MRNA) Reports Q1 Loss, Lags Revenue Estimates
Moderna (MRNA) came out with a quarterly loss of $2.52 per share versus the Zacks Consensus Estimate of a loss of $2.92. This compares to loss of $3.07 per share a year ago.
Moderna Posts Loss, Citing Seasonality of Respiratory Business
Moderna logged a first-quarter loss as revenue fell, dragged down by lower product sales, though the company said it expects demand to increase during cold and flu season later this year.
Countdown to Moderna (MRNA) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
Beyond analysts' top -and-bottom-line estimates for Moderna (MRNA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2025.
Moderna (MRNA) Stock Falls Amid Market Uptick: What Investors Need to Know
The latest trading day saw Moderna (MRNA) settling at $27.19, representing a -0.75% change from its previous close.
Can Moderna Keep the Beat Streak Alive This Earnings Season?
When MRNA reports first-quarter earnings, investors will likely focus on pipeline updates.
Moderna (MRNA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Where Will Moderna Be in 5 Years?
In the early days of the COVID-19 pandemic, Moderna (MRNA -1.89%) was a top performer, from both a share-price and an earnings perspective. As one of the leading coronavirus vaccine companies, the biotech brought in billions of dollars in annual earnings and saw its stock price jump more than 2,300% from January 2020 through early August of 2021.
Moderna (MRNA) Stock Drops Despite Market Gains: Important Facts to Note
Moderna (MRNA) reachead $24.73 at the closing of the latest trading day, reflecting a -1.85% change compared to its last close.
FDA News Just Shook Moderna. Is the Stock One to Avoid or a Bad-News Buy?
Moderna (MRNA 2.21%) has gone through its share of ups and downs in recent years, from posting soaring coronavirus vaccine revenue a few years ago to seeing demand for that product sink in the later stages of the coronavirus pandemic. Now, the biotech is trying to show the world that it can expand beyond coronavirus prevention as it has a full pipeline of programs ranging from latent viruses and rare diseases to cancer.
S&P 500 Gains and Losses Today: Moderna Stock Plunges After Resignation of FDA Vaccine Official
Major U.S. equities indexes were mixed to kick off the new trading week as U.S. trade policy remained in focus.
